ArticleFrontiers in cellular and infection microbiology2025
Determinants of functional cure in interferon-treated chronic hepatitis B: a retrospective cohort analysis of HBsAg dynamics and clinical predictors.
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Group-based trajectory modeling for declines in hepatitis B surface antigen over time accurately identifies chronic hepatitis B patients achieving functional cure: a single-center cohort study in China.Annals of medicine · 2026Article
- [A real-world study of clinical cure in children with HBeAg-positive chronic hepatitis B from the Guangxi region].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Article
- Construction and validation of a predictive model for HBsAg loss in chronic hepatitis B patients treated with Peg-IFNα-2b.Frontiers in cellular and infection microbiology · 2026Article
- Pegylated Interferon-α-Induced Functional Cure for Special Populations with Chronic Hepatitis B Virus Infection: Current Trends, Challenges and Prospection.Drug design, development and therapy · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Objectives: Functional cure of chronic hepatitis B (CHB) is the optimal goal of antiviral therapy. This study evaluates the functional cure rates in a large cohort treated with interferon (IFNα) and explores baseline predictors to optimize personalized treatment strategies. Methods: This retrospective study included CHB patients treated with IFN monotherapy or IFN combined with nucleos(t)ide analogs at Beijing You'an Hospital from 2008 to 2023. Patients were categorized into functional cure (FC) and non-functional cure (NFC) groups based on treatment outcomes. Results: Among 5288 patients, 887 (16.8%) achieved functional cure. FC patients had significantly lower baseline HBsAg, HBV DNA, and HBeAg positivity compared to NFC patients. Kaplan-Meier analysis revealed cumulative functional cure rates of 10.6%, 25.7%, and 39.9% at 48, 96, and 144 weeks, respectively. Multivariate logistic regression analysis identified lower baseline HBsAg levels, female, HBeAg negativity, lower γ-GT levels, and higher FT3 and FT4 levels as factors associated with higher functional cure rates. Patients with HBsAg <100 IU/ml had a cure rate of 58.8% within 96 weeks, compared to 11.1% for those with >1500 IU/ml. Conclusion: Early HBsAg decline is critical for functional cure. Female patients, HBeAg-negative status, and baseline HBsAg <100 IU/mL predict higher success rates.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.